Covered recipient · General Payments record
NICHOLAS DILORETO
General Payments · PY2023–2024
$876.94
- Reported across 10 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $804.06 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $207.17 | 2 |
| Novo Nordisk AS | $199.99 | 2 |
| E.R. Squibb & Sons, L.L.C. | $101.83 | 1 |
| Gilead Sciences, Inc. | $97.02 | 1 |
| Penumbra, Inc. | $76.17 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $72.43 | 1 |
| Janssen Pharmaceuticals, Inc | $49.45 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $98.05 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110507784 | CMS |
| AstraZeneca Pharmaceuticals LP | $109.12 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110508632 | CMS |
| Boston Scientific Corporation | $72.43 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092529159 | CMS |
| E.R. Squibb & Sons, L.L.C. | $101.83 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101482787 | CMS |
| Gilead Sciences, Inc. | $97.02 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133644310 | CMS |
| Janssen Pharmaceuticals, Inc | $49.45 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078051590 | CMS |
| Novo Nordisk Inc | $102.52 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108582577 | CMS |
| Novo Nordisk Inc | $97.47 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108582635 | CMS |
| Penumbra, Inc. | $76.17 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1076218122 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.